Item 8.01 Other Events.

On November 30, 2021, Allakos Inc. (the "Company") issued a press release announcing that a multicentered, randomized, double-blind, placebo-controlled Phase 2 clinical trial of subcutaneous (SC) lirentelimab in adult patients with moderate-to-severe atopic dermatitis has been initiated. The Company also announced its plans to initiate a multicentered, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of SC lirentelimab in patients with chronic spontaneous urticaria in the middle of 2022, as well as a multicentered, randomized, double-blind, placebo-controlled Phase 2 trial of SC lirentelimab in moderate-to-severe, uncontrolled asthma patients with or without an eosinophilic phenotype in Q4 2022, and clinical trials in additional indications are planned in 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit                                   Description

 99.1       Press release dated November 30, 2021

 104      Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses